This suggests that increased MCL1 activity through low-amplitude copy number gain in neuroblastoma may contribute to an aggressive phenotype in tumors without MYCN amplification, which is the strongest predictor of poor prognosis in neuroblastoma tumors [38]. This evidence concerns the gene MCL1 and neuroblastoma.